Filtered By:
Specialty: Drugs & Pharmacology
Condition: Renal Failure

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 46 results found since Jan 2013.

Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen
ConclusionsFor paracetamol versus ibuprofen, when using LSPS methods in the CPRD, it is only possible to distinguish true effects if those effects are large (hazard ratio  >  2). Due to their smaller hazard ratios, the outcomes under study cannot be differentiated from null effects (represented by negative controls) even if there were a true effect. Based on these data, we conclude that we are unable to determine whether paracetamol is associated with an increased ris k of myocardial infarction, stroke, GI bleeding, and acute renal failure compared to ibuprofen, due to residual confounding.
Source: Drug Safety - June 3, 2020 Category: Drugs & Pharmacology Source Type: research

Outcomes in Post ‐Myocardial Infarction patients similar to those of the PEGASUS‐TIMI 54 trial: a cohort study in the French national claims database
ConclusionsPatients selected using the criteria described in PEGASUS were older with more comorbidities, resulting in higher all‐cause death bleeding rates, but similar MI recurrence rates.
Source: British Journal of Clinical Pharmacology - March 26, 2017 Category: Drugs & Pharmacology Authors: Patrick Blin, Caroline Dureau ‐Pournin, Régis Lassalle, Jérémy Jové, Florence Thomas‐Delecourt, Cécile Droz‐Perroteau, Nicolas Danchin, Nicholas Moore Tags: PHARMACOEPIDEMIOLOGY Source Type: research

Outcomes in patients after myocardial infarction similar to those of the PEGASUS ‐TIMI 54 trial: A cohort study in the French national claims database
ConclusionsPatients selected using the criteria described in PEGASUS were older with more comorbidities, resulting in higher all‐cause death and bleeding rates, but similar MI recurrence rates.
Source: British Journal of Clinical Pharmacology - May 5, 2017 Category: Drugs & Pharmacology Authors: Patrick Blin, Caroline Dureau ‐Pournin, Régis Lassalle, Jérémy Jové, Florence Thomas‐Delecourt, Cécile Droz‐Perroteau, Nicolas Danchin, Nicholas Moore Tags: PHARMACOEPIDEMIOLOGY Source Type: research

The problem of atrial fibrillation in patients with chronic kidney disease.
Abstract Chronic kidney disease (CKD) is associated with the risk of multiple life-threatening complications such as: progression to chronic renal failure and cardiovascular disease including coronary heart disease, heart failure and peripheral arterial disease. Also, atrial fibrillation (AF) is common in this group of patients. Factors contributing to the occurrence of AF in patients undergoing dialysis include: age, presence of coronary heart disease, echocardiographic abnormalities (low ejection fraction, atrial enlargement, valvular calcification, left ventricular hypertrophy), heart failure, chronic obstructi...
Source: Current Vascular Pharmacology - January 15, 2016 Category: Drugs & Pharmacology Authors: Franczyk B, Gluba-Brzózka A, Ciałkowska-Rysz A, Banach M, Rysz J Tags: Curr Vasc Pharmacol Source Type: research

Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement: Meta-Analysis of Clinical Outcomes and Cost-Effectiveness.
Conclusions The present study demonstrated no significant differences in regards to mortality or stroke between the two therapeutic procedures. However, the cost-effectiveness and long-term efficacy of TAVI may require further investigation. Technological improvement and increased experience may broaden the clinical indication for TAVI for low-intermediate risk patients in the future. PMID: 26891807 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - February 19, 2016 Category: Drugs & Pharmacology Authors: Cao C, Liou KP, Pathan FK, Virk S, McMonnies R, Wolfenden H, Indraratna P Tags: Curr Pharm Des Source Type: research

Effects of Intensive Blood Pressure Control in Patients with Evident Cardiovascular Disease: An investigation using the SPRINT study data.
CONCLUSION: We confirm the beneficial effect of the intensive strategy in SPRINT study on all-cause mortality and the harmful effect on specific adverse outcomes in patients with CVD. However, in patients with low baseline SBP stroke may increase. PMID: 29512468 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - March 5, 2018 Category: Drugs & Pharmacology Authors: Vlachopoulos C, Terentes-Printzios D, Aznaouridis K, Ioakeimidis N, Xaplanteris P, Lazaros G, Tousoulis D Tags: Curr Vasc Pharmacol Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Results from A 12 Months, Randomized, Clinical Trial Comparing an Olmesartan/Amlodipine Single Pill Combination to Olmesartan and Amlodipine Monotherapies on Blood Pressure and Inflammation.
CONCLUSION: other than to be more effective in reducing blood pressure, olmesartan/amlodipine single pill combination gave also a major increase of insulin sensitivity and a decrease of inflammatory markers compared to single monotherapies. PMID: 23999037 [PubMed - as supplied by publisher]
Source: European Journal of Pharmaceutical Sciences - August 30, 2013 Category: Drugs & Pharmacology Authors: Derosa G, Cicero AF, Carbone A, Querci F, Fogari E, D'Angelo A, Maffioli P Tags: Eur J Pharm Sci Source Type: research

Drug Therapy of Apparent Treatment-Resistant Hypertension: Focus on Mineralocorticoid Receptor Antagonists
Abstract Apparent treatment-resistant hypertension (aTRH) is defined as blood pressure (BP) >140/90 mmHg despite three different antihypertensive drugs including a diuretic. aTRH is associated with an increased risk of cardiovascular events, including stroke, chronic renal failure, myocardial infarction, congestive heart failure, aortic aneurysm, atrial fibrillation, and sudden death. Preliminary studies of renal nerve ablation as a therapy to control aTRH were encouraging. However, these results were not confirmed by the Symplicity 3 trial. Therefore, attention has refocused on drug therapy. Secondary forms o...
Source: Drugs - March 19, 2015 Category: Drugs & Pharmacology Source Type: research

A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-Aspartate Angiotensin I in Healthy Subjects
AbstractDes-aspartate-angiotensin I (DAA-I) is an endogenous angiotensin peptide and a prototype angiotensin receptor agonist (ARA). It acts on the angiotensin AT1 receptor and antagonises the deleterious actions of angiotensin II. DAA-I attenuates animal models of human disease in which angiotensin II has been implicated, such as cardiac hypertrophy, neointima formation, arteriosclerosis, renal failure, post-infarction injuries, diabetes, viral infection, chemical-induced inflammation, heat stroke, cancer, and gamma radiation lethality. DAA-I crosses Caco-2 cells and is effective at sub-nanomolar concentrations. These two...
Source: Drugs in R&D - September 27, 2016 Category: Drugs & Pharmacology Source Type: research

Dabigatran - metabolism, pharmacologic properties and drug interactions.
Abstract The superiority of dabigatran has been well proven in the standard dosing regimen in prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and extended venous thromboembolism (VTE) treatment. Dabigatran, an anticoagulant with a good safety profile, reduces intracranial bleeding in patients with atrial fibrillation and decreases major and clinically relevant non-major bleeding in acute VTE treatment. However, several important clinical issues are not fully covered by currently available directions with regard to dabigatran administration. The prominat one is re...
Source: Current Drug Metabolism - April 26, 2017 Category: Drugs & Pharmacology Authors: Antonijevic N, Zivkovic I, Jovanovic L, Matic D, Kocica M, Mrdovic I, Kanjuh V, Culafic M Tags: Curr Drug Metab Source Type: research

Hypertension and cardiovascular risk: general aspects
Publication date: Available online 7 November 2017 Source:Pharmacological Research Author(s): Sverre E. Kjeldsen Hypertension is the strongest or one of the strongest risk factors for almost all different cardiovascular diseases acquired during life, including coronary disease, left ventricular hypertrophy and valvular heart diseases, cardiac arrhythmias including atrial fibrillation, cerebral stroke and renal failure. The continuous relationship between blood pressure and cardiovascular and renal events makes the distinction between high normal blood pressure and hypertension based on arbitrary cut-off values for blood p...
Source: Pharmacological Research - November 8, 2017 Category: Drugs & Pharmacology Source Type: research

Therapeutic Advances in the Management of Orthostatic Hypotension
Conclusions: Although there is no accepted protocol regarding how to manage hypertension in patients with OH, some studies favor the use of beta blockers and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, over alpha-receptor antagonists and diuretics.
Source: American Journal of Therapeutics - January 1, 2018 Category: Drugs & Pharmacology Tags: Systematic Review and Clinical Guidelines Source Type: research

The effect of Curcumin/Turmeric on blood pressure modulation: A systematic review and meta-analysis
ConclusionThe present meta-analysis suggests that consuming curcumin/turmeric may improve SBP when administered in long durations. However, more studies are needed to confirm these results.Graphical abstract
Source: Pharmacological Research - October 22, 2019 Category: Drugs & Pharmacology Source Type: research